

Solid Tumors Cancer

A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Trial Status

Active, not recruiting

Trial Runs In

14 Countries

Trial Identifier

NCT03448042 GO40311

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Genentech, Inc.

Sponsor

Phase 1

Phase

NCT03448042 GO40311

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>= 18 Years

Healthy Volunteers

No
